Tryp Therapeutics Inc.

TRYP THERAPEUTICS AND EXOPHARM LIMITED ANNOUNCE COMPLETION OF PLAN OF ARRANGEMENT

TRYP THERAPEUTICS PROVIDES UPDATE ON PLAN OF ARRANGEMENT WITH EXOPHARM LIMITED AND ANNOUNCES VOLUNTARY TRADING HALT

TRYP THERAPEUTICS ANNOUNCES 99.92% VOTES CAST BY SHAREHOLDERS IN FAVOR OF ARRANGEMENT AGREEMENT AT ANNUAL GENERAL AND SPECIAL MEETING OF SECURITYHOLDERS, AND RECEIPT OF FINAL ORDER

TRYP THERAPEUTICS OBTAINS INTERIM ORDER FOR PLAN OF ARRANGEMENT AND PROVIDES DETAILS OF SHAREHOLDER MEETING

TRYP THERAPEUTICS AND EXOPHARM LIMITED SECURE PIVOTAL 2 CENT WAIVER FROM ASX

TRYP THERAPEUTICS ANNOUNCES SIGNIFICANT MILESTONE IN ITS CLINICAL TRIAL PROGRAM FOR TRP-8803 (IV-INFUSED PSILOCIN)

TRYP THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PHASE 2a CLINICAL TRIAL FOR THE TREATMENT OF FIBROMYALGIA AT THE UNIVERSITY OF MICHIGAN

Tryp Therapeutics Inc. Announces Signing of Definitive Agreement with Exopharm Limited

Tryp Therapeutics Announces Closing of Oversubscribed Private Placement of Unsecured Convertible Notes for Gross Proceeds of AUD$3,215,000

TRYP THERAPEUTICS ANNOUNCES JASON CARROLL AS NEW CHIEF EXECUTIVE OFFICER

WITH GREAT SADNESS TRYP ANNOUNCES THE PASSING OF DAVID TOUSLEY, DIRECTOR

TRYP THERAPEUTICS RECEIVES CONFIRMATION FROM FDA TO PROCEED WITH PHASE 2A CLINICAL TRIAL IN PATIENTS WITH IBS AT MASSACHUSETTS GENERAL HOSPITAL

TRYP THERAPEUTICS SUBMITS INVESTIGATIONAL NEW DRUG (IND) APPLICATION TO US FDA FOR PLANNED PHASE 2a CLINICAL TRIAL IN PATIENTS WITH IBS AT MASSACHUSETTS GENERAL HOSPITAL

Tryp Therapeutics Announces Closing of Oversubscribed Private Placement of Secured Convertible Debentures for Gross Proceeds of AUD$2,400,000

Tryp Therapeutics Announces Private Placement of Secured Convertible Debentures for Gross Proceeds of a minimum of AUD$2,000,000

TRYP THERAPEUTICS COMPLETES PSYCHOTHERAPY TRAINING FOR PLANNED PHASE 2a CLINICAL TRIAL AT MASSACHUSETTS GENERAL HOSPITAL